PAR2 Pepducin在特应性皮炎模型中抑制炎症与瘙痒
在特应性皮炎模型中,细胞穿透性pepducin PZ-235显著抑制角质形成细胞PAR2介导的炎症因子表达和肥大细胞IL-4/IL-13,并在多种皮炎模型中减轻皮肤增厚、白细胞浸润和瘙痒。
要点
- PZ-235抑制角质形成细胞PAR2介导的NF-κB、TSLP、TNF-α和K10表达94%-98%(P<0.001)。
- PZ-235抑制肥大细胞IL-4和IL-13达68%-83%(P<0.05)。
- PZ-235减轻小鼠瘙痒51%(P<0.05),与PAR2缺陷的保护效果相当。
核心结论
- PAR2 pepducin可能作为特应性皮炎和瘙痒的疾病修饰治疗提供广泛治疗益处。
研究设计与样本
- 在特应性皮炎模型(人角质形成细胞、肥大细胞及多种小鼠皮炎模型)中测试细胞穿透性pepducin PZ-235的效果。
主要发现
- PZ-235使人角质形成细胞中PAR2介导的NF-κB、TSLP、TNF-α和K10表达抑制94%-98%(P<0.001)。
- PZ-235使肥大细胞IL-4和IL-13抑制68%-83%(P<0.05)。
- 在迟发型pepducin治疗模型中,PZ-235使恶唑酮和DNFB诱导皮炎的皮肤增厚减轻43%-100%(P<0.01),白细胞结痂减少57%(P<0.05),并抑制白细胞对PAR2激动剂的离体趋化。
- 在丝聚蛋白缺陷小鼠暴露于尘螨过敏原8周期间每日给予PZ-235,使总白细胞和T细胞浸润抑制50%-68%,表皮厚度抑制60%-77%,皮肤增厚、脱屑、抓痕和总病变严重度评分抑制46%-56%。
- PZ-235使小鼠黄蜂毒肽诱导的肥大细胞脱颗粒所致瘙痒减少51%(P<0.05),与PAR2缺陷的保护效果相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PAR2 has been proposed to contribute to lesion formation and intense itch in atopic dermatitis. Here, we tested the ability of a cell-penetrating pepducin, PZ-235, to mitigate the potentially deleterious effects of PAR2 in models of atopic dermatitis. PZ-235 significantly inhibited PAR2-mediated expression of inflammatory factors NF-κB, TSLP, TNF-α, and differentiation marker K10 by 94%-98% (P < 0.001) in human keratinocytes and suppressed IL-4 and IL-13 by 68%-83% (P < 0.05) in mast cells. In delayed pepducin treatment models of oxazolone- and DNFB-induced dermatitis, PZ-235 significantly attenuated skin thickening by 43%-100% (P < 0.01) and leukocyte crusting by 57% (P < 0.05), and it inhibited ex vivo chemotaxis of leukocytes toward PAR2 agonists. Daily PZ-235 treatment of filaggrin-deficient mice exposed to dust mite allergens for 8 weeks significantly suppressed total leukocyte and T-cell infiltration by 50%-68%; epidermal thickness by 60%-77%; and skin thickening, scaling, excoriation, and total lesion severity score by 46%-56%. PZ-235 significantly reduced itching caused by wasp venom peptide degranulation of mast cells in mice by 51% (P < 0.05), which was comparable to the protective effects conferred by PAR2 deficiency. Taken together, these results suggest that a PAR2 pepducin may confer broad therapeutic benefits as a disease-modifying treatment for atopic dermatitis and itch.
引用
- Barr TP, Garzia C, Guha S, et al. PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models. J Invest Dermatol. 2018. PMID: 30287285. doi:10.1016/j.jid.2018.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。